Farmácia/Notícias da Indústria
CDC | Uso de vacina de mRNA contra COVID-19 após relatos de miocardite entre vacinados – “A continuação do uso das vacinas de mRNA contra a COVID-19 em todos os grupos etários recomendados vai prevenir a morbidade e a mortalidade por COVID-19 em números que excedem muito o número de casos esperados de miocardite.”
9 Jul, 2021 | 16:06h
Comentário no Twitter
In a new @CDCMMWR, the Advisory Committee on Immunization Practices recommends everyone 12 & older get a #COVID19 vaccine. The benefits of vaccination in preventing illness & death outweigh the rare risk of heart inflammation after vaccination. More: https://t.co/iPjbhU5jeV. pic.twitter.com/IggrZ4DX7L
— CDC (@CDCgov) July 6, 2021
Sensibilidade reduzida da variante Delta do SARS-CoV-2 a neutralização por anticorpos.
9 Jul, 2021 | 16:04hReduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization – Nature
Comentários: Study highlights need for full Covid vaccination to protect against Delta variant – STAT E How does the Delta variant dodge the immune system? Scientists find clues. – The New York Times
Comentário no Twitter (fio – clique para saber mais)
Just published @Nature
Delta variant protection by mRNA and AZ vaccines requires 2-doses, little neutralizing antibody (nAb) with 1-dose, and insufficient nAb with prior covidhttps://t.co/TOgJdMe0g6 pic.twitter.com/KWLb9rBZ44— Eric Topol (@EricTopol) July 8, 2021
Perspectiva | “‘Bom demais para ser verdade’: dúvidas em torno do estudo que mostrou redução de 77% na mortalidade da COVID-19.”
9 Jul, 2021 | 16:00h‘Too good to be true’: Doubts swirl around trial that saw 77% reduction in COVID-19 mortality – Science (poucos artigos gratuitos por mês)
M-A | Pouco benefício no uso de relaxantes musculares para adultos com dor lombar não específica.
9 Jul, 2021 | 15:49hComentário: New analysis finds muscle relaxant drugs to be largely ineffective for low back pain – News Medical
Estudos relacionados: M-A: Effectiveness of treatments for acute and subacute mechanical non-specific low back pain E RCT: Little benefit from osteopathic manipulative treatment on activity limitations in patients with nonspecific subacute and chronic low back pain E M-A: Little benefit from antidepressants for low back pain E Meta-analysis: Little benefit from antidepressants for the treatment of back pain and osteoarthritis E ACP/AAFP Guideline: Nonpharmacologic and pharmacologic management of acute pain from non–low back, musculoskeletal injuries in adults
Comentários no Twitter
Muscle relaxants are largely ineffective for #lowback #pain. They might increase the risk of side effects.
Published today in @bmj_latest ⬇️
Proud to be a part of this excellent team led by @AidanCashin
Paper: https://t.co/4p7gd7PJIe pic.twitter.com/3CLvL7JUfI
— Hayley Leake (@HayleyLeake) July 8, 2021
This systematic review found very low certainty evidence that muscle relaxant drugs for the treatment of acute low back pain might provide a small and not clinically meaningful improvement in pain intensity at two weeks or less @Pain_NeuRa https://t.co/HGwN4Oekrq
— The BMJ (@bmj_latest) July 8, 2021
M-A | Comparação de eficácia e segurança de vancomicina, linezolida, tedizolida e daptomicina no tratamento de pacientes com infecção suspeita ou comprovada de pele e partes moles.
9 Jul, 2021 | 15:47h
Comentário no Twitter
🆕💥 Network Meta-Analysis @InfectDis_Ther
20 RCTs N=7804
Comparative Efficacy& Safety of Vancomycin,Linezolid,Tedizolid, and Daptomycin in Treating Patients with Suspected or Proven cSSTI
Linezolid was superior to vancomycin in improving clinical successhttps://t.co/qlZfXoWfaa pic.twitter.com/tO3sIoOMY4— Antibiotic Steward 🇵🇸💔Bassam Ghanem (@ABsteward) June 20, 2021
Coorte nacional prospectiva no Chile mostrou que a efetividade da CoronaVac foi de 65,9% para Covid-19 sintomática, 87,5% para hospitalizações, 90,3% para admissões em UTI e 86,3% para mortes.
8 Jul, 2021 | 09:57hEffectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile – New England Journal of Medicine
Relacionado: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years. E WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. E Brazilian town experiment shows mass vaccination can wipe out COVID-19.
Comentário no Twitter
Chile's data on Sinovac CoronaVac in NEJM: not controlled study. Model details pic 2
– doses 28 days apart (like Serrana trial)
– symptomatic disease 65.9% (65-67)
– hospitalization 87.5% (87-88)
– intensive care 90.3% (89-91)
– Covid death 86.3% (85-88)
https://t.co/CB1U8Ar163 pic.twitter.com/4HwASRCnwQ— Hilda Bastian, PhD (@hildabast) July 7, 2021
Novas evidências sugerem que a vacina Sputnik contra COVID é segura e eficaz.
8 Jul, 2021 | 09:55hMounting evidence suggests Sputnik COVID vaccine is safe and effective – Nature
Resistência antibiótica durante e depois da COVID-19.
8 Jul, 2021 | 09:52hAntibiotic resistance during and beyond COVID-19 – JAC-Antimicrobial Resistance
Perspectiva | Pessoas com problemas imunológicos deveriam tomar uma 3ª dose de vacina?
8 Jul, 2021 | 09:51hShould People With Immune Problems Get Third Vaccine Doses? – The New York Times (poucos artigos gratuitos por mês)
Relacionado: [Preprint] 3rd AstraZeneca shot gives strong immunity. E Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.
Comentário sobre estudo | Diminuição no uso de antibióticos para otite média aguda e sinusite aguda após implementação da imunização infantil com vacina pneumocócica conjugada (pneumococcal conjugate vaccine – PCV13).
8 Jul, 2021 | 09:44h